Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
G1 Therapeutics, Inc. (GTHX)
|
Add to portfolio |
|
|
|
| Price: |
$24.28
| | Metrics |
| OS: |
51.7
|
M
| |
|
|
| Market cap: |
$1.26
|
B
| |
|
|
|
Net cash:
|
$53.3
|
M
| |
$1.03
|
per share
|
|
EV:
|
$1.2
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($162)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 51.3 | 31.5 | 45.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 |
| Revenue growth | 63.0% | -30.5% | | | | | -100.0% | |
| Cost of goods sold | 3.7 | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 47.6 | 29.5 | 45.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 |
| Gross margin | 92.7% | 93.6% | 100.0% | | | | | 100.0% |
| Selling, general and administrative | 100.4 | 95.7 | 68.5 | 40.0 | | | | |
| Research and development | 83.3 | 76.2 | 73.3 | 89.0 | 70.7 | 53.9 | 25.2 | 12.7 |
| General and administrative | | | | | 18.6 | 7.1 | 5.2 | 3.2 |
| EBIT | -136.2 | -142.5 | -96.5 | -129.0 | -89.3 | -61.0 | -30.4 | -15.4 |
| EBIT margin | -265.4% | -452.6% | -213.0% | | | | | -2954.8% |
| Pre-tax income | -145.9 | -147.4 | -97.8 | -122.4 | -85.3 | -60.1 | -30.3 | -20.3 |
| Income taxes | 1.7 | 0.9 | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -147.6 | -148.4 | -99.3 | -122.4 | -85.3 | -64.9 | -34.7 | -21.7 |
| Net margin | -287.6% | -471.3% | -219.2% | | | | | -4155.2% |
| |
| Diluted EPS | ($3.38) | ($3.54) | ($2.62) | ($3.27) | ($2.56) | ($3.57) | ($23.33) | ($16.13) |
| Shares outstanding (diluted) | 43.6 | 41.9 | 37.9 | 37.5 | 33.3 | 18.2 | 1.5 | 1.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|